Background: Cervical cancer has a high mortality rate.
Aim: We aimed to study the expression of micro ribonucleic acid 152 (miR-152) in cervical cancer and its influence on cisplatin (DDP) resistance.
Methodology: Cervical cancer Hela cells were divided into control, DDP, DDP + mimic nc and DDP + miR-152 mimic groups.
Results: DDP, DDP + mimic nc and DDP + miR-152 mimic groups had lower cell survival rate, smaller number of single clones and cells penetrating the membrane, and higher apoptosis rate and miR-152 expression than those of the control group (P<0.05). Compared with DDP and DDP + mimic nc groups, the cell survival rate, number of single clones and number of cells penetrating the membrane significantly decreased, while the apoptosis rate and miR-152 expression increased in the DDP + miR-152 mimic group (P<0.05). ERBB3 was a downstream target gene of miR-152. Hela cells transfected with miR-152 mimic had lower protein expressions of Snail, ERBB3, Akt2, p-Akt and c-myc than those of NC cells (P<0.05).
Conclusion: MiR-152 suppresses the proliferation, migration and infiltration of cervical cancer cells and reduces their resistance to DDP chemotherapy by inhibiting the expressions of proteins in the and pathways.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10782345 | PMC |
| http://dx.doi.org/10.4314/ahs.v23i2.28 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MTIOT: Identifying HPV subtypes from multiple infection data.
Comput Struct Biotechnol J
December 2024
Key Laboratory of Systems Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China.
Persistent infection with high-risk human papillomavirus (hrHPV) is a major cause of cervical cancer. The effectiveness of current HPV-DNA testing, which is crucial for early detection, is limited in several aspects, including low sensitivity, accuracy issues, and the inability to perform comprehensive hrHPV typing. To address these limitations, we introduce MTIOT (Multiple subTypes In One Time), a novel detection method that utilizes machine learning with a new multichannel integration scheme to enhance HPV-DNA analysis.
View Article and Find Full Text PDFAn exploration of the natural and acquired immunological mechanisms to high-risk human papillomavirus infection and unmasking immune escape in cervical cancer: A concise synopsis.
Tzu Chi Med J
December 2024
Department of Obstetrics and Gynecology, College of Medicine, University of Babylon, Hilla, Iraq.
The most common STD that triggers cervical cancer is the human papillomavirus. More than 20 types of human papillomavirus (HPV) can induce uterine cervical cancer. Almost all women acquire genital HPV infection soon after their first intercourse, with most of them clearing the virus within 3 years.
View Article and Find Full Text PDFVvax001, a Therapeutic Vaccine for Patients with HPV16-positive High-grade Cervical Intraepithelial Neoplasia: a Phase II Trial.
Clin Cancer Res
January 2025
University Medical Center Groningen, Groningen, Netherlands.
Purpose: Human papillomavirus (HPV) infection is the major cause of (pre)malignant cervical lesions. We previously demonstrated that Vvax001, a replication-incompetent Semliki Forest virus (SFV) vaccine encoding HPV type 16 (HPV16) E6 and E7, induced potent anti-E6 and -E7 cytotoxic T-cell responses. Here, we investigated the clinical efficacy of Vvax001 in patients with HPV16-positive cervical intraepithelial neoplasia grade 3 (CIN3).
View Article and Find Full Text PDFThe effect of waiting time on ovarian cancer survival in oncology centres, Addis Ababa, Ethiopia: a retrospective cohort study.
BMC Womens Health
January 2025
School of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Ovarian cancer is a leading cause of mortality worldwide. The third most prevalent gynecological cancer globally, following cervical and uterine cancer, and the third leading cause of cancer-related mortality among women in Sub-Saharan Africa, including Ethiopia. The time ovarian cancer patients have to wait between diagnosis and initiation of treatment are the indicators of quality in cancer care and influence patient outcomes.
View Article and Find Full Text PDFAssociation of blood group types and clinico-pathological features of gynecological cancers (GCs).
BMC Cancer
January 2025
Molecular Diseases & Diagnostics Division, Infinity Biochemistry, Infinity Solutions Unlimited, Sajjad Abad, Chattabal, Srinagar, 190010, Kashmir, India.
Background: Gynecological cancers (GCs) affect the reproductive system of females, and are of multiple types depending on the affected organ most common of which are cervical, endometrial, ovarian cancers. Among different risk factors for GCs, ABO blood group system is considered as one of the pivotal contributing factors for increased susceptibility of GCs. The aim of our study was to report on the demographics of GC patients and to investigate the relationship between the ABO blood group system and the risk of acquiring GC in our population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!